Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
-
Brussels Education Unions Schedule Major November Protest Over Funding and Reforms
-
Crowds Gather at San Francisco Park for Elizabeth Holmes Lookalike Tournament
-
Making Your Home Safer for Aging Parents: Accessibility Renovations That Add Value
-
New 401k Gold IRA Investment Guide Explains the Best Way to Invest in Gold for Retirement (2026 Update)
-
iPS Cell Research Accelerates Drug Discovery for ALS and Spinal Cord Injury
-
Central Tokyo Apartment Rents Forecast to Rise 11% by 2030
-
Rene Eyre Revisits Autobiographical Performance 'Say A Little Prayer' in London
-
London Museum Granted 24/7 License Ahead of November Opening
-
UAE's HCT Holds Record Graduation and Announces Major Training Expansion
-
Dana White Confirms Flight to Washington for Trump Meeting on Press Secretary Role
-
NASA Awards $10B Lunar Contract Framework to SpaceX, Blue Origin
-
Dengue Fever Expands Into High Himalayas as Climate Change Warms Nepal
-
Katy Perry Tells Fans Ex-Husband Russell Brand 'Should Be in Jail' During UK Concert
-
IoT Refrigerator Hacks Disrupt Blood Labs and Supermarkets Across Europe and US
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 13, 2026 to report its fourth quarter 2025 financial results, and provide a corporate update.
A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.
Webcast: https://investors.modernatx.com
The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
A.Jones--AMWN
